Latanoprost Qualigen

Latanoprost, the active ingredient in Latanoprost Qualigen, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients. The medication works by enhancing the outflow of aqueous humor through the uveoscleral pathway, providing sustained pressure reduction.

GNH USA supplies Latanoprost Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used in ocular hypotensive therapy to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers intra‑ocular pressure to prevent development of glaucoma. Normal‑tension glaucoma: assists in maintaining target intra‑ocular pressure.

Latanoprost may cause ocular and systemic adverse reactions; most are mild and reversible.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length or density - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision

Serious or Rare Side Effects: - Allergic reaction (e.g., swelling, rash) - Severe ocular inflammation (uveitis, keratitis) - Sudden loss of vision

When prescribing Latanoprost, clinicians should consider several safety precautions.

Monitor intra‑ocular pressure: ensure therapeutic reduction is achieved. Assess for ocular infection: avoid use in active conjunctivitis or keratitis. Avoid in patients with active uveitis: may exacerbate inflammation. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Hypersensitivity: discontinue if allergic reaction occurs. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: may increase risk of ocular side effects. - Use with ophthalmic corticosteroids: may reduce hypotensive effect.

Moderate Interactions (Monitor Closely): - Combination with carbonic anhydrase inhibitor eye drops: additive IOP‑lowering effect, monitor pressure. - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation. - Systemic beta‑blockers: monitor for additive systemic hypotensive effects.